Targeting vascular risk in patients with metabolic syndrome but without diabetes.

@article{Athyros2005TargetingVR,
  title={Targeting vascular risk in patients with metabolic syndrome but without diabetes.},
  author={Vasilios G Athyros and Dimitri P. Mikhailidis and Athanasios A. Papageorgiou and Triandafillos P Didangelos and A. Peletidou and Drosia Kleta and Asterios Karagiannis and Anna I. Kakafika and Konstantinos Tziomalos and Moses S Elisaf},
  journal={Metabolism: clinical and experimental},
  year={2005},
  volume={54 8},
  pages={
          1065-74
        }
}
There are no prospective data on the effect of a multitargeted treatment approach on cardiovascular disease (CVD) risk reduction in nondiabetic patients with metabolic syndrome (MetS). Furthermore, the optimal hypolipidemic drug treatment in these patients remains controversial. In this prospective, randomized, open-label, intention-to-treat, and parallel study, 300 nondiabetic patients with MetS, free of CVD at baseline, were studied for a period of 12 months. Age- and sex-matched subjects… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 20 CITATIONS

Statins for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis.

Layli Eslami, Shahin Merat, Reza Malekzadeh, Siavosh Nasseri-Moghaddam, Hermineh Aramin
  • The Cochrane database of systematic reviews
  • 2013